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subscales such as dry mouth, stick saliva, taste impairment, and tooth 
pain the differences were found, which were both statistical (p < 
0.05) and clinically (difference >10 points) significant when compared 
with prior RT.  
Conclusions: The study showed that the most treatment-related QoL 
issues, which were deteriorated during treatment, improved in the 
first year after RT, but still dry mouth, stick saliva, taste impairment, 
and tooth pain are more pronounced than prior RT. However, these 
issues did not influence on significant difference between global QoL 
prior and 1 year after RT. 
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Purpose/Objective: To ascertain the reasons for recurrences in 
Radiation Therapy (RT), ChemoRadiation Therapy (CRT) and Surgical 
Treatment (ST) of early stages glottic laryngeal cancer. 
Materials and Methods: A retrospective analysis of 136 patients with 
SCC of the larynx T1-2 from 1992 to 2007. T1 - 67 patients, T2 - 69 
patients, including T1-2N+ 4 (2.9%) patients. 91 patients with glottic 
cancer received RT, CRT, and ST. Overall 5-year survival rate and 
median survival time: 84,4% and 82 months (Kaplan Meier Survival 
curve). Recurrences were observed in 14 (15.4%) patients, of which 
only 3 (21.4%) died from progression. 
Results: In RT and CRT - 50 patients, tumor recurrence was observed 
in 6 (12%) patients. With the defeat of the anterior commissure tumor 
(ACT) recurrence was observed in 4 (16.7%) patients, without anterior 
commissure tumor (WACT) - in 2 (7.7%) patients. The risk of 
recurrence increases by 2 times in ACT. It should be noted that 5 of 
the 6 recurrences detected after chemoradiation therapy, and 1 
patient in combination with distant metastases. After RT - only 1 
recurrence. Overall 5-year survival rate and median survival: CRT - 
87.5% and 59 months, RT - 75% and 111 months (p), respectively. Only 
2 patients died from progression. In the ST group (41 patients) - 8 
(19.5%) patients with recurrences. In 17 patients with ACT- 6 (35.3%) 
relapsed. In 24 patients WACT - 2 (8.3%) relapsed. Thus the risk of 
recurrence after surgical treatment is 4.2 times higher in patients 
with ACT and in 2 times higher compared with RT. It should be noted, 
that in 9 WACT patients received laser destruction (LD) recurrence 
detected in only 1 patient (11%). Cordectomy (CE) and partial vertical 
laryngeal resections (PVLR) performed 32 patients - relapses were 
observed in 7 (21.8%), of which CE – in 2 (12.5%) of 16 patients, PVLR - 
in 5 (31.3%) of 16. Of the these 7 patients: 2 (28.6%) with well 
differentiated tumor (WDT) and 5 (71.4%) with moderate 
differentiated tumor; surgical resections with negative margins found 
only in 1 patient. Overall 5-year survival rate and median survival - 
90.3% and 91 months. Only 1 patient died from progression. 
Conclusions: The basic reason for relapse - the incorrect treatment 
strategy. 1) The most effective treatment - radically RT, regardless of 
the degree of tumor differentiation and mode of fractionation. ACT 
increases the risk of recurrence in 2 times. 2) LD in WACT patients 
(T1a) – the same good method as RT. 3) Partial laryngeal resections 
(CE, PVLR) in WDT the same good methods as RT. ACT defeat risk of 
recurrence is 2 times higher than after RT. Perhaps a more wide 
excision of the tumor will improve the results of organ-saving 
operations. Surgical resections with pathologic margins negative for 
tumor requires additional treatment. ST needs further investigation 
and correction. 4) CRT is not inferior to other treatments in respect of 
remission of the disease, but the median survival with CRT is 2 times 
lower than with RT (p = 0.001) and 1.5 times lower than in the ST (p = 
0.01) , eliminating chemotherapy treatments for cancer of the larynx 
in the early stages. 
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Purpose/Objective: Anaplastic thyroid carcinomas (ATC) are among 
the most aggressive human malignancies. Only 1-2% of thyroid 
carcinomas are anaplastic, but the disease contributes to ≈ 50% of the 
mortality of thyroid cancers and median survival is ≤ 10 months. Our 
aim is to update recommendations for RT in the context of new 
irradiation techniques. 
Materials and Methods: A search of the French and English literature 
was performed with terms: thyroid carcinoma, anaplastic, 
chemoradiation, radiation therapy, surgery. Level-based evidence 
remains limited in the absence of prospective studies and the small 
size of retrospective series of this rare tumor. 
Results: Surgery when possible should be as complete as possible but 
without mutilation given the poor prognostic of ATC. It often consists 
of debulking resection only. It should be followed by systematic 
chemoradiation in ATC. Initiation of treatment is an emergency given 
the fast tumor doubling time of these tumors. The most promising 
results of chemoradiation to date have been shown in series of 
radiation therapy (± acceleration) combined with doxorubicin ± 
taxanes or cisplatin. Adjuvant chemotherapy (doxorubicin, cisplatine 
and/or taxane-based), given the metastatic potential of ATC, 
warrants further investigations. Data on neoadjuvant chemotherapy 
are missing. Intensity modulated radiation therapy offers clear 
dosimetric advantages and has the potential to improve tumor and 
nodal (posterior neck, mediastinum) coverage, i.e. locoregional 
control while optimally sparing the spinal cord, larynx, parotids, 
trachea and esophagus. PET-CT and MRI may be used for RT planning. 
Conclusions: Chemoradiation with debulking surgery whenever 
possible is the main stay of treatment of ATC. EBRT using IMRT has the 
potential to improve local control. Taxane-doxorubicin concomitant 
chemoradiotherapy is worth further investigations. 
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Purpose/Objective: Adenoid cystic carcinoma is a rare malignant 
neoplasma that accounts for less than 5% of head and neck cancers. 
Surgery is considered the mainstay treatment to the disease, 
however, clear surgical margins are difficult to achieve. Radiotherapy 
(RT) may improve locoregional control. The purpose of this study is to 
evaluate the effectiveness of RT for patients with head and neck 
adenoid cystic carcinoma with an attempt to identify significant 
prognostic factors. 
 Materials and Methods: A retrospective review of 25 patients who 
received RT in our department between January 2003 and May 2011 
was performed. Median age was 56 (28-79); 13 patients was female, 
12 patients was male. The subsite distribution was paranasal sinuses 
40% (n=10), oral cavity 24%(n=6), submandibular 20% (n= 5), parotid 
gland 16% (n=4). T and N stage distributions were T1:0%, T2:24%, 
T3:28%, T4:48% and N0:80%, N1:8%, N2:12%. None of the patients had 
distant metastasis at the time of diagnosis. Overall TNM stage 2, 3, 4 
distributions were 24%, 24%, 52%, respectively. Two patients had base 
of skull involvement. Ten (40%) patients had grade 3 tumor. Sixteen 
patients (64%) had microscopic perineural invasion; and 10 (40%) 
patients had positive surgical margin. Twenty-two (88%) patients had 
surgery and all patients received RT (22:postoperative, 
1:preoperative, 2:radiation alone). Conventional RT applied to 13 
patients, conformal RT applied to 12 patients. Median RT dose was 64 
Gy (40-70) with 2 Gy daily dose fraction. Six patients received 
cisplatin based chemotherapy concomitant to RT.  
Results: After median follow-up time of 46 (8.37-102) months, 18 
(72%) patients were alive (n=15 without disease, n=3 with disease) and 
7 (28%) patients were exitus. Five patients had distant, 1 patient had 
local and distant, 1 patient had local failure. Most common distant 
metastasis site was lung. Median overall survival time was 80.7 (51.75-
110) months. On univariate analysis patients with tumor stage (T4 vs 
T2+3; p=0.005) and overall stage (TNM stage 4 vs 2+3; p=0.009) 
showed worse overall survival. Close or positive surgical margin 
